Press Enter to search · Esc to close
A cluster of new 2025 papers reframes GLP-1 drugs as long-horizon metabolic tools — with real promise after bariatric surgery, a tantalizing brain-protection signal, and one safety question worth taking seriously.
The shots that started as diabetes medicine and became weight-loss icons are quietly rewriting their own job description. The 2025 evidence points to a multi-organ story — with caveats worth knowing.
A new wave of 2025 research suggests GLP-1 and dual GIP/GLP-1 drugs do more than shrink waistlines and tame A1c — they may protect the heart at the cellular level, and hint at effects we are only beginning to map.
Average results hide individual reality. A new protocol pairs a metabolic challenge with machine learning to score how your body specifically answers herbal extracts.
Semaglutide and tirzepatide rewrote the metabolic playbook. The pipeline behind them is already bifurcating — and what arrives next will look less like one blockbuster shot and more like a stack.
Semaglutide and tirzepatide started as obesity treatments. A wave of moderate-quality evidence is pushing them toward something bigger — and asking new questions about inflammation, the heart, and even cancer.
The shots that started as diabetes drugs and exploded as weight-loss icons are turning out to do a lot more than mute hunger. New research traces their fingerprints across the hindbrain, the kidney's salt switches, and the hormone that tells you it's lunchtime.
A 95-patient multi-site study suggests advanced hybrid closed-loop pumps — long the domain of type 1 diabetes — can safely tighten glucose control in insulin-using adults with type 2. The results are encouraging, and worth reading carefully.
New 2025 data suggests GLP-1 receptor agonists are doing more than shrinking waistlines — with signals across the brain, kidneys, and operating room. Here's what the evidence actually says.
Three 2025 studies suggest the new generation of metabolic drugs reaches further than the scale — into addiction risk, liver fat, and the realities of treating people over 65. The evidence is promising, and still maturing.